Anti-CD20 should be the first-line treatment in high-risk membranous nephropathyClinical Kidney JournalApril 10, 202310.1093/ckj/sfad075Cited by 13SaveCiteExport RISWatch citationsRelated PapersNo related papers foundPowered by citation graph analysis